01 January 2001
Skin prick test response to enzyme enolase of the baker's yeast (Saccharomyces cerevisiae) in diagnosis of respiratory allergy.
Marita Nittner-Marszalska, Irena Wójcicka-Kustrzeba, Ewa Bogacka, Janusz Patkowski, Rafał DobekMed Sci Monit 2001; 7(1): CR121-124 :: ID: 421176
Abstract
BACKGROUND: The aim of the study is to prove that Saccharomyces cerevisiaeenolase, the major allergen of the baker's yeast, induces allergic immediate response in patients withinhalant allergy sensitized to Candida albicans extract.
MATERIAL AND METHODS: The study was performedin three groups of patients: I. 20 atopic patients with respiratory allergy sensitized to Candida albicansand inhalant allergens (mite, feather, pollens) II. 30 patients with respiratory allergy, positive skintests to inhalant allergens but negative skin tests to Candida albicans and other fungi; III. 20 nonatopic,healthy individuals. Skin prick test of purified enolase from Saccharomyces cerevisiae (bakers yeast)at concentration 1 and 10 mg/ml was performed in all groups. The results were documented planimetrically.
RESULTS: 95% of patients sensitized to Candida albicans extract showed positive skin reactions to Saccharomycescerevisiae enolase, 10% of patients of group II and none of the patients of the control group had positiveskin responses to enolase. The mean wheal size (mm2) in skin prick test to Candida albicans, Saccharomycescerevisiae enolase at concentration 10 mg/ml was x = 15.17 +/- 11.08, 15.76 +/- 19.67 and at concentration1 mg/ml 10.02 +/- 10.49, respectively.
CONCLUSIONS: 1. Saccharomyces cerevisiae enolase induces an immediateallergic reaction in skin in subjects with respiratory allergy and positive skin prick test results toCandida albicans and other fungi. 2. Enolase can be an important allergenic component of the Candidaalbicans extract.
Keywords: fungal allergy, Saccharomyces cerevisiae enolase, baker's yeast enolase
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952